Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Rising cancer numbers indicate urgent need for advancements in cancer research, and stem cell research is rising to meet the challenge. < ...

The market's underestimating how well each of these companies should be able to capitalize on their opportunities.

Session: Poster Session B Abstract title:Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and ...

The Philadelphia market has gained recognition not only for its cell and gene therapy sector but also its real estate scene and talent pool. Vittoria Biotherapeutics, Interius BioTherapeutics and ...

We recently published a list of 10 Stocks That Analysts Think Will Go Up. In this article, we are going to take a look at ...

The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with ...

Looking for a biopharma job in Pennsylvania? Check out the BioSpace list of six companies hiring life sciences professionals ...

Bullish option flow detected in Iovance Biotherapeutics (IOVA) with 9,622 calls trading, 2x expected, and implied vol increasing almost 27 ...

Under the agreement, Vector Laboratories will provide non-proprietary protein sequences of antibodies having known and disclosed manufacturability issues, such as poor yield and high propensity for ...